Current Assets
Work in process
Pfizer Work in process decreased by 7.3% to $6.04B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 16.9%, from $7.27B to $6.04B. Over 4 years (FY 2020 to FY 2024), Work in process shows an upward trend with a 8.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ4 2015
Last reportedQ3 2025
Parent metricInventories
How to read this metric
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Detailed definition
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peer comparison
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
Metric ID:
inv_work_in_progressHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.39B | $4.47B | $4.42B | $4.84B | $5.19B | $4.54B | $5.52B | $6.13B | $6.41B | $6.52B | $5.69B | $6.27B | $7.07B | $7.27B | $6.10B | $5.55B | $6.51B | $6.04B |
| QoQ Change | — | +1.8% | -1.0% | +9.5% | +7.2% | -12.6% | +21.6% | +11.1% | +4.6% | +1.7% | -12.7% | +10.3% | +12.7% | +2.8% | -16.0% | -9.0% | +17.3% | -7.3% |
| YoY Change | — | — | — | — | +18.4% | +1.6% | +24.8% | +26.6% | +23.4% | +43.5% | +3.1% | +2.3% | +10.3% | +11.5% | +7.3% | -11.5% | -7.9% | -16.9% |
| % of Inventories | 447.3% | 478.0% | 48.8% | 541.7% | 550.8% | 136.5% | 61.5% | 109.1% | 109.2% | 460.1% | 55.8% | 186.6% | 242.4% | 262.8% | 56.2% | 198.8% | 276.0% | 281.9% |
| Share Change | — | +30.7pp | -429.1pp | +492.9pp | +9.1pp | -414.3pp | -75.0pp | +47.7pp | +0.1pp | +350.9pp | -404.3pp | +130.8pp | +55.7pp | +20.5pp | -206.6pp | +142.6pp | +77.2pp | +5.9pp |
Range$4.39B – $7.27B
CAGR+7.8%
Avg YoY Growth+9.7%
Median YoY Growth+8.8%
Work in process at Other Companies
Frequently Asked Questions
- What is Pfizer's work in process?
- Pfizer (PFE) reported work in process of $6.04B in Q3 2025.
- How has Pfizer's work in process changed year-over-year?
- Pfizer's work in process decreased by 16.9% year-over-year, from $7.27B to $6.04B.
- What is the long-term trend for Pfizer's work in process?
- Over 4 years (2020 to 2024), Pfizer's work in process has grown at a 8.3% compound annual growth rate (CAGR), from $4.43B to $6.10B.
- What does work in process mean?
- The value of goods currently in the middle of the manufacturing process.